HELSINKI, August 3, 2021 / PRNewswire / – Nanoform, An Innovative Company Enabling Nanoparticle Medicine, Announces Proof-of-Concept Studies Can Now Be Performed for Boehringer Ingelheim to Evaluate the Added Value of Nanoform’s Award-Winning CESS® technology can contribute to its drug development projects.
Both sides performed a framework service contract (MSA).
Christian jones, CCO of Nanoform, commented: “Wider adoption of the latest technological innovations is essential to address the low success rates of new drug candidates in pharmacy. We are excited to collaborate with Boehringer Ingelheim to assess how our proprietary CESS® can help more innovative therapies reach the patients who need them. This is the first step towards what we hope will be a long and fruitful partnership between our companies. “
For more information, please contact:
Peter Hänninen, General Counsel
[email protected] / +358 50 353 0408
For all investor relations questions, please contact:
Henri von haartman, director of investor relations
[email protected] / +46 7686 650 11
About the nanoform
Nanoform is an innovative company enabling medicine based on nanoparticles. Nanoform works in collaboration with pharmaceutical and biotechnology partners around the world to give hope to patients in the development of new and improved drugs using the technologies of the Nanoform platform. The company is focused on reducing clinical attrition and improving the performance of drug molecules through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key drug solubility and bioavailability issues and building new applications. drug administration. Nanoform shares are listed on the first segment of the Nasdaq First North Growth Market at Helsinki (teleprinter: NANOFH) and Stockholm (teleprinter: NANOFS). Certified advisor: Danske Bank A / S, Finland Branch, +358 40 562 1806. For more information, please visit http://www.nanoform.com.
This press release contains forward-looking statements, including, without limitation, statements regarding Nanoform’s strategy, business plans and direction. The words may “,” will “,” could “,” should “,” should “,” expect “,” plan “,” anticipate “,” intend “, believe”, “estimate” , “Predict”, “project,” “potential”, “continue”, “target” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. forward-looking statements contained in this press release are based on the current expectations and beliefs of management and are subject to a number of risks, uncertainties and important factors which may cause actual events or results to differ materially from those expressed or implied by any forward-looking statement.statements contained in this press release, including, without limitation, anything relating to business, operations, clinical trials, supply chain, strategy ie, Nanoform’s objectives and expected timelines, competition from other companies and other risks specified in Nanoform’s published prospectus (on May 22, 2020) in connection with Nanoform’s initial public offering (the “Prospectus”) under the heading “Risk Factors” and in our other documents or documents provided to the Finnish Financial Supervisory Authority in connection with the Prospectus. Nanoform cautions you not to place undue reliance on forward-looking statements, which speak only as of the date they are made. Nanoform disclaims any obligation to publicly update or revise such statements to reflect any change in expectations or in the events, conditions or circumstances on which such statements may be based, or which may affect the likelihood that actual results will differ from those set forth in forward-looking statements. All forward-looking statements contained in this press release represent the views of Nanoform only as of the date hereof and should not be construed as representing its views as of any later date.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: